Search

Your search keyword '"Aldigeri, R"' showing total 3 results
Start Over Author "Aldigeri, R" Topic macular edema
3 results on '"Aldigeri, R"'

1. Effectiveness of Pegylated Interferon Alpha-2a in Post-Uveitic Macular Edema Previously Responding to Non-Pegylated Interferon.

Author

De Simone L, Gentile P, Aldigeri R, Mastrofilippo V, Bolletta E, Gozzi F, Adani C, Salvarani C, and Cimino L

Subjects
Humans, Retrospective Studies, Female, Male, Middle Aged, Adult, Treatment Outcome, Follow-Up Studies, Injections, Subcutaneous, Aged, Antiviral Agents therapeutic use, Fluorescein Angiography, Macular Edema drug therapy, Macular Edema etiology, Macular Edema diagnosis, Polyethylene Glycols therapeutic use, Interferon-alpha therapeutic use, Recombinant Proteins therapeutic use, Recombinant Proteins administration & dosage, Visual Acuity physiology, Tomography, Optical Coherence
Abstract

Purpose: To evaluate the efficacy of pegylated interferon (PEG-IFN) alpha-2a to treat post-uveitic relapsing macular edema (ME) after withdrawal of non-PEG IFN alpha-2a or 2b to maintain treatment efficacy., Methods: This retrospective study investigated subjects with post-uveitic ME who received weekly subcutaneous PEG-IFN alpha-2a injections. Comparisons between baseline central macular thickness (CMT) and best-corrected visual acuity (BCVA) and those at all follow-up visits were made., Results: Six patients (nine eyes) were treated and followed up for six months. CMT (mean [standard deviation]) decreased from 375[117] to 283[39] μm after one month ( p  < 0.001), remaining significantly lower up to the final follow-up visit at six months (275[38] μm, p  = 0.008), and BCVA (0.21[0.16] logMAR at baseline) showed an improvement of 0.12[0.11] logMAR ( p  = 0.026) at six months. Neither recurrences nor any serious adverse events were recorded., Conclusions: Post-uveitic ME patients were effectively and safely treated with PEG-IFN alpha-2a.

Published
2024
Full Text
View/download PDF

2. Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema.

Author

De Simone L, Sangiovanni A, Aldigeri R, Mastrofilippo V, Bolletta E, Invernizzi A, Fares L, Pipitone N, Fontana L, Salvarani C, and Cimino L

Subjects
Antineoplastic Agents administration & dosage, Female, Fluorescein Angiography methods, Follow-Up Studies, Fundus Oculi, Humans, Intravitreal Injections, Macular Edema diagnosis, Macular Edema etiology, Male, Middle Aged, Retrospective Studies, Tomography, Optical Coherence methods, Treatment Outcome, Uveitis diagnosis, Interferon alpha-2 administration & dosage, Macular Edema drug therapy, Uveitis complications, Visual Acuity
Abstract

Purpose : To assess the efficacy of interferon (IFN) alpha-2a in the treatment of post-uveitic refractory macular edema (ME). Methods : Retrospective cohort of patients with post-uveitic refractory ME, who received subcutaneous IFN alpha-2a injections for at least 3 months. Baseline central macular thickness (CMT) and best-corrected visual acuity (BCVA) were compared with those at follow-up visits up to 12 months. Results : Thirty-seven patients were included. Treatment duration (median [interquartile range]) was 14[8-24] months with a follow-up of 17[10-38] months. CMT (mean [standard deviation]) decreased from 438[140] to 335[119] μm after 1 month (p < 0.0001) and remained significantly lower up to 12 months (286[98] μm, p = 0.001). BCVA (0.48[0.33] logMAR at baseline) improved by 0.26[0.33] logMAR (p = 0.001) at 12 months. There were 14 recurrences. Seven patients had treatment side effects, without serious adverse events. Conclusions : IFN alpha-2a was effective, safe, and well tolerated in treating post-uveitic refractory ME.

Published
2020
Full Text
View/download PDF

3. Cataract Surgery with Intraocular Lens Implantation in Juvenile Idiopathic Arthritis-Associated Uveitis: Outcomes in the Era of Biological Therapy

Author

Michele De Maria, Raffaella Aldigeri, Chantal Adani, Fabrizio Gozzi, Luigi Fontana, Valentina Mastrofilippo, Michela Cappella, Danilo Iannetta, Alessandro Invernizzi, Alessandro De Fanti, Antonio Moramarco, Marco Coassin, Carlo Salvarani, Elena Bolletta, Luca Cimino, Alberto Neri, Luca De Simone, Bolletta E, Coassin M, Iannetta D, Mastrofilippo V, Aldigeri R, Invernizzi A, de Simone L, Gozzi F, De Fanti A, Cappella M, Adani C, Neri A, Moramarco A, De Maria M, Salvarani C, Fontana L, and Cimino L

Subjects
medicine.medical_specialty, genetic structures, medicine.drug_class, medicine.medical_treatment, intraocular lens, Glaucoma, Arthritis, Intraocular lens, Antimetabolite, Article, uveitis, 03 medical and health sciences, 0302 clinical medicine, juvenile idiopathic arthriti, intraocular len, Ophthalmology, medicine, IOL, JIA, Macular edema, 030203 arthritis & rheumatology, OL, biologicals, cataract surgery, juvenile idiopathic arthritis, business.industry, General Medicine, Phacoemulsification, Cataract surgery, medicine.disease, eye diseases, 030221 ophthalmology & optometry, Medicine, sense organs, business, biological, Uveitis
Abstract

This study compared the outcomes of cataract surgery with intraocular lens (IOL) implantation in patients with juvenile idiopathic arthritis (JIA)-associated chronic anterior uveitis treated with antimetabolite drugs and systemic corticosteroids (Non-Biological Group) versus patients treated with antimetabolites and biological drugs (Biological Group). A cohort of patients with cataract in JIA-associated uveitis undergoing phacoemulsification with IOL implantation was retrospectively evaluated. The main outcome was a change in corrected distance visual acuity (CDVA) in the two groups. Ocular and systemic complications were also recorded. The data were collected preoperatively and at 1, 12, and 48 months after surgery. Thirty-two eyes of 24 children were included: 10 eyes in the Non-Biological Group and 22 eyes in the Biological Group. The mean CDVA improved from 1.19 ± 0.72 logMAR preoperatively to 0.98 ± 0.97 logMAR at 48 months (p = 0.45) in the Non-Biological Group and from 1.55 ± 0.91 logMAR preoperatively to 0.57 ± 0.83 logMAR at 48 months (p = 0.001) in the Biological Group. The postoperative complications, including synechiae, cyclitic membrane, IOL explantation, glaucoma, and macular edema, were not statistically different between the two groups. An immunosuppressive treatment with biological drugs can improve the visual outcome after cataract surgery in patients with JIA-associated uveitis, but it does not significantly reduce postoperative ocular complications.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results